HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Clorox’s Purchase Of Burt’s Bees Confirms Arrival Of Naturals To Mainstream

This article was originally published in The Rose Sheet

Executive Summary

Clorox's acquisition of Burt's Bees is the latest example of a consumer products giant zeroing in on a small natural products company in order to hitch a ride on a trend that increasingly is infiltrating the mass market, research firm Kline and Company says

You may also be interested in...



Robitussin Gets Natural With Honey, Ivy Leaf, Eucalyptus Supplements For Cough Relief

GSK launches Robitussin Naturals drug-free cough and cold remedies in the first naturals offering under the top-selling OTC drug brand. The line includes liquids and gummies for adults and children formulated with honey, ivy leaf and eucalyptus.

Growth Approaches: Entrepreneur P&G, Top Brand Church & Dwight, Practice Patience Clorox

P&G, Church & Dwight and Clorox executives say firms are looking to add brands to portfolios. P&G's developing assets through a brand creation project; C&D seeks top brands, largely in non-US markets; and Clorox looks for opportunities in select ‘spaces’ in US health, wellness and personal care.

Burt’s Bees Hopes Third Time’s A Charm In Oral Care With P&G As Provider

Clorox and Procter & Gamble embarked on a strategic licensing partnership to market Burt’s Bees toothpastes, available now in mass retail doors. Billed as simple formulas for adults and kids, with or without fluoride, the line marks the third swing at toothpaste for the iconic natural brand.

Related Content

UsernamePublicRestriction

Register

OM002409

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel